Lung Cancer News and Research RSS Feed - Lung Cancer News and Research Twitter

Lung cancer is the world's most common cancer and kills more people than any other cancer. In 2008, approximately 1.52 million new cases of lung cancer were diagnosed worldwide, with 1.31 million people dying from the disease.(14) In the United States, an estimated 161,840 deaths, accounting for 29 percent of all cancer deaths, occurred in 2008, according to the American Cancer Society (ACS).
Tobacco-related cancer risks increase among men in China

Tobacco-related cancer risks increase among men in China

In China, smoking now causes nearly a quarter of all cancers in adult males. The finding comes from a large study published early online in CANCER, a peer-reviewed journal of the American Cancer Society, as part of a Special Issue on Lung Cancer in China. High uptake rates of cigarette smoking in teenaged males and continued use in adulthood foreshadow even greater tobacco-related cancer risks for the nation. [More]
Researchers develop new method that can target drug delivery to the lung

Researchers develop new method that can target drug delivery to the lung

Researchers from Columbia Engineering and Columbia University Medical Center have developed a new method that can target delivery of very small volumes of drugs into the lung. [More]
Huntington’s disease prevention breakthrough? An interview with Professor Lesley Jones

Huntington’s disease prevention breakthrough? An interview with Professor Lesley Jones

Huntington’s disease is an inherited disease which, whilst quite rare, is one of the more common inherited neurodegenerative diseases. About 1 in 6,000 people in the UK are at risk and what’s horrible about this disease is that if one of your parents has it, then you have a fifty-fifty chance of inheriting it. [More]
UC Davis Health System research shows that increasing minimum wage may reduce smoking rates

UC Davis Health System research shows that increasing minimum wage may reduce smoking rates

In addition to restricting when and where tobacco is used at work, UC Davis Health System research shows that employers can do something else to reduce smoking: raise wages. [More]
MACC1 gene can help predict better treatment options for patients with Klatskin carcinoma

MACC1 gene can help predict better treatment options for patients with Klatskin carcinoma

Bile duct cancer is rare and is usually detected too late. Often only extensive liver surgery can help or, in rare cases, liver transplantation. But which patients will benefit from surgery and which will not, because their risk of cancer recurrence is too high? With the oncogene MACC1 as a biomarker, physicians for the first time have a tool to decide which treatment option is best for patients with Klatskin carcinoma, one type of bile duct cancer. [More]
Brain tumor is not always the death sentence

Brain tumor is not always the death sentence

Only half of brain cancers actually start in the brain. The rest - as in the case of former president Jimmy Carter - are metastatic tumors from cancer that originated elsewhere in the body. [More]
LCA commends Congress for establishing life-saving initiative on lung cancer

LCA commends Congress for establishing life-saving initiative on lung cancer

Today, Laurie Fenton Ambrose, President & CEO of Lung Cancer Alliance (LCA) hailed the establishment of the first bi-partisan Lung Cancer Caucus in the United States House of Representatives and thanked Congressman Rick Nolan (D-MN), Congressman Frank LoBiondo (R-NJ) and Congresswoman Lois Capps (D-CA) for leading this effort. [More]
Despite increased life expectancy, British people suffer from more medical ailments

Despite increased life expectancy, British people suffer from more medical ailments

People in the UK are living longer but are coping with more medical ailments causing illness or disability in their older years, according to a major new international study published in The Lancet today (Thursday 27 August). [More]
New study provides framework for establishing value-based pricing for new cancer drugs

New study provides framework for establishing value-based pricing for new cancer drugs

At a time when cancer drug prices are rising rapidly, an innovative new study provides the framework for establishing value-based pricing for all new oncology drugs entering the marketplace. Using a highly sophisticated economic model, researchers from Winship Cancer Institute of Emory University and Georgia Institute of Technology used an example of a new lung cancer drug. [More]
New NCCN Guidelines for Patients and NCCN Quick Guide for Kidney Cancer published

New NCCN Guidelines for Patients and NCCN Quick Guide for Kidney Cancer published

Kidney Cancer is among the 10 most diagnosed cancers in both men and women in the United States, and it is estimated that more than 60,000 new cases of kidney cancer will be diagnosed in 2015. [More]
Enrollment completed for REOLYSIN Phase II study in patients with advanced or metastatic NSCLC

Enrollment completed for REOLYSIN Phase II study in patients with advanced or metastatic NSCLC

Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with previously treated advanced or metastatic non-small cell lung cancer ("NSCLC") (IND 211). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario. [More]
FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

Boehringer Ingelheim today announced that both the U.S. Food and Drug Administration and the European Medicines Agency have accepted filing applications for afatinib for the treatment of patients with advanced squamous cell carcinoma (SCC) of the lung progressing after treatment with first-line chemotherapy. [More]
Study reveals potential health risks associated with burning of incense in indoor environments

Study reveals potential health risks associated with burning of incense in indoor environments

The burning of incense might need to come with a health warning. This follows the first study evaluating the health risks associated with its indoor use. The effects of incense and cigarette smoke were also compared, and made for some surprising results. The research was led by Rong Zhou of the South China University of Technology and the China Tobacco Guangdong Industrial Company in China, and is published in Springer's journal Environmental Chemistry Letters. [More]
Electronic triggers can help identify, reduce follow-up delays in evaluation for cancer diagnosis

Electronic triggers can help identify, reduce follow-up delays in evaluation for cancer diagnosis

Electronic triggers designed to search for key data, developed by researchers at Baylor College of Medicine and Michael E. DeBakey Veterans Affairs Medical Center, were able to identify and reduce follow-up delays for patients being evaluated for a diagnosis of colon or prostate cancer. [More]
Benitec Biopharma announces closing of U.S. initial public offering of ADSs

Benitec Biopharma announces closing of U.S. initial public offering of ADSs

Benitec Biopharma Limited, a clinical-stage biotechnology company, is pleased to announce the closing of its U.S. initial public offering of 1,500,000 American Depositary Shares (ADSs), representing 30,000,000 fully paid ordinary shares of Benitec, together with warrants to purchase 500,000 ADSs, representing 10,000,000 fully paid ordinary shares. [More]

IQWiG dossier assessment finds added benefit of afatinib in patients with certain mutations

Afatinib (trade name: Giotrif) has been approved since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI). [More]
Failure To Rescue After Complications Defines Lung Cancer Resection Survival

Failure To Rescue After Complications Defines Lung Cancer Resection Survival

The variation in mortality rates among patients undergoing lung cancer resection in US hospitals has been attributed by a cohort study to differences in failure-to-rescue rates after the development of complications. [More]
DelMar closes on $2.6 million registered direct placement

DelMar closes on $2.6 million registered direct placement

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced the closing of a registered direct placement (Placement) with $2.6 million received from the offering. [More]
Landmark 'basket study' shows efficacy of vemurafenib in multiple nonmelanoma BRAFV600-mutated cancers

Landmark 'basket study' shows efficacy of vemurafenib in multiple nonmelanoma BRAFV600-mutated cancers

Researchers from Memorial Sloan Kettering Cancer Center have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients' tumors rather than where their cancer originated. [More]
EnGeneIC begins Phase 1 Tailored-EDV trial for advanced solid tumor

EnGeneIC begins Phase 1 Tailored-EDV trial for advanced solid tumor

EnGeneIC Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, today announced that the first patient has been dosed in its Phase 1 Tailored-EDV trial. The trial is being conducted at the Northern Cancer Institute in Sydney, Australia. [More]
Advertisement